I believe the strong Galera results and their BTD award coupled with our lack of BTD award negatively influenced the deal-making calculus on B-OM significantly. My speculation is that the first term sheet fell through because the potential partner saw risk rise too much. As a result, their offer likely was lowered to a number Leo was unwilling to entertain.
When it was an open field, pharma may have paid up big for our B-OM results sans BTD. Now that there is an almost certain success story in Galera with BTD, B-OM likely needs to be proven more if we want very large money.
This is all my read on the situation. Take it for what it is.
(1)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links